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STUDY OF DIABETES IN PREGNANCY
OBJECTIVE— In adults, adiponectin is reduced in association with excess adiposity, type 2
diabetes, and hyperinsulinemia. We assessed whether adiponectin was 1) present in the fetal
circulation, 2) altered in the fetal circulation in the presence of maternal diabetes, and 3) had
relations to fetal cord blood insulin or adiposity.
RESEARCH DESIGN ANDMETHODS— We assessed adiponectin in cord blood in a
large cohort of singleton offspring of diabetic mothers (ODM; n 134) and control mothers (n
45).
RESULTS— Adiponectin was present in cord blood and, in ODM, was higher in those
delivered at later gestational ages (Spearman r 0.18, P 0.03). Adiponectin was slightly lower
in ODM than control subjects (ODM 19.7  6.1 vs. control 21.8  5.3 g/ml; P  0.04),
although this difference could potentially reflect different gestational ages in the two groups
(ODM 37.6 1.5 and control 40.1 1.1 weeks). In contrast to adults, adiponectin levels in the
fetus were unrelated to the degree of adiposity, blood insulin, or leptin in either control subjects
or ODM.
CONCLUSIONS— Adiponectin is present in cord blood but does not show expected phys-
iological relations with adiposity as observed in adults.
Diabetes Care 26:2244–2249, 2003
Adipose tissue expresses a variety ofsecretory proteins of importance tometabolic and vascular disease. Re-
cently, adiponectin, a 244–amino acid
adipocyte-derived protein (1) has been
described that is paradoxically reduced in
obesity (2) and inversely related to leptin
concentrations (3), despite being solely
derived from adipose tissue in humans.
Both type 2 diabetes and relative insulin
resistance (in nondiabetic subjects) are
associated with decreased adiponectin
concentrations (4,5), while improvement
of insulin sensitivity by either weight re-
duction (6) or administration of thiazo-
lidinediones (7) is associated with
increased adiponectin concentrations.
Furthermore, in people matched for BMI,
higher adiponectin concentrations are
protective against later development of
type 2 diabetes (8).
Exposure to maternal diabetes in
utero is associated with increased adipos-
ity at birth (9), as well as increases in fetal
leptin (10) and insulin (11). Further-
more, the presence of maternal diabetes
during pregnancy influences the long-
term health of offspring with increases in
future risk of obesity (12,13), type 2 dia-
betes (14), and impaired glucose toler-
ance (15–17).
Adiponectin has not been previously
assessed in cord blood specimens. We
wished to examine whether 1) adiponec-
tin was present in cord blood, 2) relations
to adiposity, sex, and circulating insulin
and leptin observed in adults were also
present in utero, and 3) offspring of moth-
ers with type 1 diabetes, a group at high
risk of later development of metabolic dis-
ease, would have lower concentrations of
adiponectin at birth.
RESEARCH DESIGN AND
METHODS
Recruitment and clinical protocol
Recruitment, which began in January
1999 and ended in May 2001, took place
in eight hospital-based antenatal centers
in Scotland. A total of 250 women with
type 1 diabetes consented to participate in
the study (a 94% participation rate of
those enrolled in and planning to deliver
in the centers), and cord blood samples
were obtained from 200 (80%). The 200
samples were further restricted to those in
whom 1) there was no evidence of hemo-
lysis of cord blood (by visual inspection),
2) cord blood had been collected within
20 min collection time for remaining sam-
ples: 2 min (1–7) [median (IQR)], and 3)
cord blood had been centrifuged and
plasma frozen within 60 min [time from
collection to freezing for remaining sam-
ples: 14 min (6–23)], as previously de-
scribed (18). Of 151 offspring of type 1
diabetic mothers (ODM) potentially
available after these restrictions, stored
samples were available for adiponectin as-
say in 142. A total of 134 participants
were included in the main analysis, and
eight offspring who had been adminis-
tered glucocorticoid in the 24 h before
delivery were considered separately. A re-
view of charts revealed that 27 mothers
(20%) had been hospitalized during preg-
nancy due to hypertensive problems (9
for pregnancy-induced hypertension and
18 for preeclampsia). Twenty mothers
(15%) had previously diagnosed thyroid
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disease, 7 (5%) had asthma, and 1 had
previously diagnosed epilepsy.
A convenience sample of control
mothers, who had no history of obstetric
or metabolic disease, and in which rou-
tine screening for gestational diabetes (us-
ing national guidelines: http://www.
sign.ac.uk/guidel ines/ ful l text /55/
section8.html) was negative were
recruited from routine obstetric fol-
low-up clinics after the 34th week of
pregnancy in the same centers. Of the 145
women who gave initial consent, cord
samples were attempted in 75 and ob-
tained in 70. Forty-nine collections met
the above restriction criteria, and samples
were available for adiponectin assay in 46.
One participant had received glucocorti-
coid in the 24 h before delivery and was
not considered.
All clinics offer antenatal care deliv-
ered by a multidisciplinary team com-
prised of obstetricians, diabetologists,
specialist midwives, diabetes specialist
nurses, and dietetic support. Local man-
agement protocols for treatment of type 1
diabetes in pregnancy were followed.
Data on clinical outcome, including ce-
sarian section, intercurrent medical con-
ditions, and hypertensive conditions of
pregnancy were obtained by chart review.
Gestational ages were calculated from es-
timated dates of delivery (EDDs) from
chart review. EDD was derived from the
date of last menstrual period (LMP) when
available or by ultrasound when there was
either a conflict with dates as assessed by
LMP (6 days) or when LMP was un-
available. HbA1c was monitored at indi-
vidual centers, as prescribed by local
clinical protocols. Samples were sent in
the first trimester, and 20 and 30 weeks of
gestation were used for measurement us-
ing a single assay (BioRad Variant, nondi-
abetic reference range 4.4 –5.7%; Bio-
Rad, Hercules, CA) at a central reference
laboratory (Western General Hospital,
Edinburgh, U.K.).
Weight was measured at birth and,
for offspring born between 33 and 42
weeks of gestation, further expressed as
an SD score, as previously described (19).
Individual birth weights are compared
with mean (MCELL) and SD (SDCELL),
which are derived from 26,000 nondia-
betic deliveries in cells specific for sex,
week of gestation, and parity (0 vs. 1).
The Z score is calculated as ([birth
weight  MCELL]/SDCELL). Skinfold
thickness at subscapular and triceps was
measured using Holtain calipers by pedi-
atricians at each site, and a centrally
agreed protocol that is available in writing
at the time of measurement was followed.
Skinfolds were not measured in all sub-
jects. However, there were no significant
differences in baseline demographic or
biochemical measures between those
with and without skinfold measurements
in either control subjects or ODM (data
not shown). All mothers gave informed
consent. Protocols were approved by the
local ethical committees.
Collections of cord bloods and
assays
After delivery, 20 ml cord blood was col-
lected from the umbilical vein, after cord
clamping, and put into lithium heparin at
ambient temperature. Depending on local
circumstances, samples were then either
transferred to local laboratories for cen-
trifugation or centrifuged in situ before
initial storage of plasma at 20°C and
eventual central storage at70°C (after a
median [IQR] of 11[5–21] days). Previ-
ous analyses in this group have estab-
lished that insulin is unstable when the
collection of blood from umbilical vein is
delayed for 20 min or freezing is de-
layed 60 min. By contrast, insulin
propeptides are stable for at least 30 min
after cord sampling and 24 h before freez-
ing (18). For the purposes of this investi-
gation, hormonal measures were only
included if collected from cord within 20
min and frozen within 60 min.
Plasma insulin, 32-33 split proinsu-
lin, leptin, and glucose were assayed as
previously described (18). In two cases
(both control subjects), insulin concen-
trations were below the detection limit of
the assay (2 pmol/l). These data have been
included with an assigned value of 1.9
pmol/l. These assays display low cross-
reactivity with other insulin species.
Adiponectin was assayed with a ra-
dioimmunoassay kit specific for human
adiponectin (HADP-61HK; Linco Re-
search, St. Charles, MO) after 1:500 dilu-
tion. Samples were analyzed in two
batches, with an intra-assay coefficient of
variation (CV) 1.8–6.2% and interassay
CV 6.9–9.3% for duplicates over a range
of adiponectin concentrations.
Statistical analysis
Data were analyzed using standard soft-
ware (SAS, Cary, NC). In several cases
(insulin, proinsulin, and 32-33 split pro-
insulin) measures were not normally dis-
tributed; therefore, log-transformed
values were used to approximate normal
distributions. Differences between con-
trol women and women with type 1 dia-
betes were assessed by unpaired Student’s
t test or, where further predictor variables
were included, by general linear models.
The relation of adiponectin to other vari-
ables was examined by Spearman correla-
tion and adjusted using partial correlation
for sex and gestational age separately in
ODM and control subjects. As we have
previously demonstrated (18) that 32-33
split proinsulin concentrations are more
stable than insulin in sampling conditions
at birth, analysis of the relation of adi-
ponectin to both 32-33 split proinsulin
and insulin is included.
RESULTS
Anthropometric and hormonal
measures in ODM versus control
subjects
Mothers with type 1 diabetes were of sim-
ilar age and parity as control mothers,
while their offspring were heavier, more
likely to be delivered by caesarian section,
and delivered 2 weeks earlier on average
than control subjects (Table 1). In keep-
ing with this, SD scores for birth weight
were dramatically higher in ODM, being
on average almost 2 SD above that ex-
pected in the population and significantly
greater than in control subjects (Table 1).
More detailed anthropometric mea-
sures were available in a subset (control
subjects, n  18 and ODM, n  55).
ODM were of similar length (crown-heel:
ODM 50.9  2.4 and control subjects
50.7  2.2 cm; P  0.88) but had in-
creased subscapular (ODM 7.3  2.2 vs.
control 5.6  2.0 cm; P  0.01) and tri-
ceps (ODM 7.8  3.1 vs. control 6.1 
2.47 cm; P  0.04) skinfold thickness.
Relation of adiponectin to length of
gestation, anthropometric, and
hormonal measures
Adiponectin was present in cord blood,
with concentrations ranging between 4.8
and 34.7 g/ml. Values of adiponectin
were normally distributed in both control
subjects and ODM (Shapiro-Wilk statis-
tic: 0.98 and 0.99, respectively) and were
unrelated to delays in sample collection or
freezing in either ODM or control subjects
(P 0.5 for all data not shown). In ODM,
adiponectin concentrations were higher
Lindsay and Associates
DIABETES CARE, VOLUME 26, NUMBER 8, AUGUST 2003 2245
in those delivered at later gestational ages
(Fig. 1 and Table 1). This was not appar-
ent in control subjects, although the range
of gestational ages at delivery was much
narrower (Fig. 1 and Table 1).
In ODM, adiponectin concentrations
were lower in boys than girls (means 
SE: boys 18.1  0.8 vs. girls 21.1  0.7
g/ml; P  0.006), a difference that re-
mained significant after adjustment for
gestational age (linear or linear and quad-
rilateral terms, P 0.005 for effect of sex
for both models). By contrast in control
subjects, adiponectin concentrations
tended to be higher in boys than girls,
although this did not achieve significance
(boys 23.3 1.1 vs. girls 21.0 1.1 g/
ml; P  0.14).
In absolute terms, adiponectin con-
centrations were significantly lower in
ODM (ODM 19.7  6.1 vs. control sub-
jects 21.8  5.3 g/ml; P  0.04). This
difference was confined to boys (ODM
18.2 0.7 vs. control subjects 22.9 0.7
g/ml; P  0.001), with no significant
difference in girls (ODM 21.1  0.7 vs.
control subjects 20.8  1.2 g/ml; P 
0.81).
Adiponectin concentrations were un-
related to mode of delivery in both ODM
(vaginal 19.0 1.0, elective cesarian sec-
tion 20.1  0.9, and emergency cesarian
section 19.8 0.9 g/ml; P 0.66) and
control subjects (vaginal 21.6 1.0, elec-
tive cesarian section 22.6  1.8, and
emergency cesarian section 21.3  2.2
g/ml; P  0.85), even after adjustment
for gestational age at delivery and sex
(ODM, P  0.56 and control, P  0.82).
There were no significant relations of
adiponectin to anthropometric or hor-
monal measures at birth (Table 2). In par-
ticular, measures reflecting adiposity (Z
score of birth weight, skinfold thick-
nesses, and cord leptin) did not show the
negative relations with adiponectin that
we hypothesized would be present. This
was also the case in boys and girls consid-
ered separately (data not shown) and
where correlations were not adjusted for
gestational age at delivery (subscapular
skin thickness in control subjects re-
mained significant, r  0.52; other rela-
tions were not significant). Adiponectin
was unrelated to cord insulin or 32-33
split proinsulin (Table 2). In addition, in
114 women in whom HbA1c measure-
ments after the 26th week of pregnancy
were available (6.9 0.9%), there was no
relation with cord adiponectin (Spearman
r 0.05, P 0.59). By contrast, insulin,
32-33 split proinsulin, and leptin are sig-
nificantly related to the Z score for weight
in ODM in this group (Spearman r 
0.55, 0.42, and 0.43, respectively; P 
0.0001 for all). Adiponectin was unre-
lated to cortisol in cord blood and was no
different in the small groups of ODM who
had been administered glucocorticoid in
the 24 h before delivery (ODM: 19.7 
6.1 g/ml, n  134 vs. ODM given glu-
cocorticoids: 20.0  7.1 g/ml, n  8).
CONCLUSIONS— Adiponectin is a
novel product of adipocytes of potential
importance to the later development of
metabolic disease. We found that adi-
ponectin is present in cord blood at rela-
tively high levels—two- to threefold
higher than that found in adults using the
same assay (20,21). Notably, however, re-
lations of adiponectin to adiposity found
in adults largely appear to be absent at
birth.
Figure 1—Adiponectin concen-
trations in cord blood in ODM
and control subjects. One ODM
subject delivered at 29 weeks
(adiponectin 12.0 mcg/ml, data
not shown). Relation of gesta-
tional age to adiponectin: ODM,
Spearman r  0.18, P  0.03;
and control subjects, r  0.01,
P  0.98. F, ODM; E, control
subjects.
Table 1—Characteristics of mothers and offspring
Control mothers
Mothers with
type 1 diabetes P*
n 45 134
Age (years) 28.9  6.1 29.7  5.7 0.43
Duration of diabetes (years) — 13.3  7.4 —
Parity
0 19 (42) 61 (45)
1 20 (44) 53 (40) 0.84
1 6 (13) 20 (15)
Children (boys/girls) 21/24 66/68 0.76
Gestational age at delivery (weeks) 40.1  1.1 37.6  1.5 0.001
Delivery
Vaginal 30 (67) 41 (31)
Elective caesarian 9 (20) 48 (36) 0.001
Emergency caesarian 6 (13) 45 (34)
Birth weight (kg)
Boys 3.75  0.51 3.81  0.74 0.01†
Girls 3.36  0.49 3.76  0.64 0.001†
Z weight of offspring‡ 0.33  1.10 1.94  1.51§ 0.001
Cord insulin (pmol/l) 22.4 (15.0–39.6) 112 (58–218) 0.001
Cord leptin (ng/ml) 8.7 (4.1–16.7) 32.0 (14.6–54.4) 0.001
Cord adiponectin (g/ml) 21.8  5.3 19.7  6.1 0.04
Data are means SD, n(%), or median (IQR). *P value in unpaired t, Wilcoxon, or 2 test, as appropriate;
†birth weights are unadjusted, and the P value for difference is dependent on maternal diabetes status and
adjusted for gestational age at delivery; ‡Z weight is an SD score compared with standard values for
gestational age, sex, and maternal parity; §n  133, 1 child (gestation age at delivery, 29 weeks) was not
included since a standardized birth weight was not available.
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Adiponectin concentrations have not
been previously reported in cord blood.
Given that there has been postulation as
to the effects of adiponectin on insulin
sensitivity (22–24), -oxidation of fats
(25), and inflammatory pathways (26),
the presence of adiponectin in utero al-
lows for potentially important effects on
early growth and development. While it is
likely that, at birth, adiponectin is largely
derived from fetal adipose tissue, we do
not have data to directly assess this. It is
possible that adiponectin may be derived
from maternal circulation or from other
tissues, notably of the placenta, as is the
case for leptin (27).
Adiponectin is solely derived from
adipocytes in adults (2). Despite this, its
presence is paradoxically reduced in obe-
sity, and an inverse relation of adiponec-
tin to measures of adiposity has been
found in all adult studies (5,8,28–30).
Unexpectedly, we found no inverse rela-
tion of adiponectin to a variety of mea-
sures that may reflect adiposity (adjusted
birth weight, skinfolds, and cord leptin)
in either ODM or control subjects. Adi-
ponectin was positively related to sub-
scapular skinfold measures in control
subjects, although this result was not in
accordance with other measures of adi-
posity. Some of the measures of adiposity
might be criticized; several investigators
were used at the various centers for mea-
suring skinfolds, which likely reduced
measurement precision. Additionally, we
lack a direct measure of body composi-
tion. Nevertheless, it appears unlikely
from our data that there is a strong rela-
tionship between adiposity and adi-
ponectin at birth. By contrast and as we
previously reported (18), other hormonal
measures, such as insulin and 32-33 split
proinsulin, are highly and significantly as-
sociated with adjusted birth weight and
leptin in this group.
The mechanism by which increased
adiposity results in lower adiponectin
concentrations in adults is unknown.
Adiponectin appears to be especially re-
lated to visceral fat mass in adults (20).
We did not assess centrality of fat distri-
bution, and it remains possible that a re-
lationship with visceral fat exists at birth.
Adiponectin is downregulated by glu-
cocorticoids in vitro (31,32). In our
study, although numbers were small,
there was no evidence of modulation of
adiponectin concentrations by glucocor-
ticoids in vivo. Similarly, while vaginal
delivery is associated with an increase in
cord cortisol in this group (data not
shown), no difference was seen in adi-
ponectin by mode of delivery. We do not
have detailed measures of other factors
during delivery, such as the duration of
intravenous infusions, and cannot
exclude the effects of these on cord
adiponectin.
Insulin probably does not directly in-
fluence adiponectin concentrations in
adults. While in vitro studies have pro-
duced conflicting results (31,32), insulin
administration in vivo to patients with
type 1 diabetes does not seem to acutely
modify adiponectin concentrations (33)
and adiponectin is not altered in response
to meals (4). The lack of relation between
adiponectin and cord insulin suggests
that, as in adults (33), circulating insulin
may have little effect on adiponectin in
utero. It should be noted, however, that in
our study we did not measure maternal
insulin antibodies, which are frequently
present in cord blood (34) and allow pas-
sage of maternal insulin into the fetal cir-
culation (35). The presence of antibodies
could conceivably influence the relation
of adiponectin to cord insulin; neverthe-
less, relations of insulin to birth weight
and leptin were readily apparent in our
study.
Adiponectin increased modestly with
gestational age at birth in ODM but not in
the control group. However, few partici-
pants in the control group were born at
gestational ages 38 weeks. Thus, while
we found differences in adiponectin con-
centration between male ODM and con-
trol subjects, we cannot exclude the
possibility that this arises as a result of the
difference in gestational age at delivery
between the two groups.
Adiponectin level has also been found
to be higher in adult women than men
(29,30), although this sex difference is
not present in all populations studied (5).
Recently, downregulation of adiponectin
by androgens has been demonstrated in
animal models, forming a potential basis
for these differences (36). Our data sug-
gest that the sex difference in adiponectin
is not normally present at birth in control
subjects. By contrast, the expected sex dif-
ference was found in ODM. The reason
for this is unclear. Boys have relatively
higher lean mass than girls at birth (37).
Though we lack detailed measures of
body composition, the absence of a rela-
tion of adiponectin to adjusted birth
weight and leptin makes it unlikely that
subtle changes in body composition un-
derpin the sex difference in ODM. At
birth, androgen concentrations are higher
in boys than girls (38) but do not appear
to be influenced by the presence of mater-
nal diabetes (39). We did not measure an-
drogens directly, but it would appear
unlikely that there is a major difference
confined to the diabetic group.
Finally, current assays only measure
monomeric adiponectin, and although
the protein circulates in trimeric, hexam-
eric, and larger forms, it has been suggested
that altered states of oligomerization may
have functional consequences (40). Adi-
ponectin is also subject to glycosylation,
which may have potential functional ef-
fects (41). It is possible that these proper-
ties of adiponectin are altered in ODM.
In summary, we found that adiponec-
tin is present in human cord blood. The
relations with adiposity found in adult
studies do not appear to be present at
birth and, despite marked differences in
adiposity, insulin, and leptin at birth,
there are at most modest changes in adi-
ponectin of the offspring of mothers with
type 1 diabetes compared with control
subjects.
Table 2—Correlation of adiponectin to an-
thropometric and hormonal measures
Control
subjects ODM
n 45 134
Z score of birth weight† 0.21 0.14
Gestational age at delivery 0.06 0.18*
Leptin 0.13 0.02
Insulin 0.12 0.0
32-33 split proinsulin 0.20 0.05
Cortisol 0.03 0.05
Cord glucose 0.15 0.14
n 18 55
Crown-heel length 0.10 0.09
Triceps skin thickness 0.18 0.05
Subscapular skin thickness 0.52* 0.08
Spearman correlation coefficients (r) of adiponectin
versus anthropometric and hormonal measures in
cord blood at birth. All analyses are adjusted for sex
and gestational age at delivery except the Z score (no
adjustment) and gestational age at delivery (sex-ad-
justed only). *P  0.05; †birth weight Z score: SD
score of birth weight in offspring grouped for gesta-
tional age, sex, and parity (n  133).
Lindsay and Associates
DIABETES CARE, VOLUME 26, NUMBER 8, AUGUST 2003 2247
Acknowledgments— This study was sup-
ported by a project grant (K/MRS/50/C2726)
from the Chief Scientist Office of the Scottish
Office. P.J.H. received funding from National
Institutes of Health Grants DK-35747 and DK-
58108, the American Diabetes Association,
and the U.S. Department of Agriculture.
We thank Kimber L. Stanhope for her ex-
pert technical assistance in performing the adi-
ponectin assays.
The study would not have been possible
without the contribution of the many people
who collected data at the different centers. Ab-
erdeen Maternity Hospital: Dr. Donald W.M.
Pearson, Dr. Gordon D. Lang, Dr. Peter
Danielan, Dr. David J. Lloyd, Dr. J. Anne Reid,
Sister Lesley Mowat, and Fiona MacGregor.
Ayrshire Central Hospital: Dr. J. Niall
MacPherson, Dr. H. Gordon Dobbie, Dr. D.
Andrew W. Collier, Dr. Fiona Barnes, Sister
Barbara Stewart, Sister Jean McCulloch, Sister
Anne Reid, and Sister Ruby Barr. Bellshill Ma-
ternity Hospital: Dr. David M. Matthews, Dr.
Andrew D.B. Harrower, Dr. Dina MacLellan,
Sister Trish McCue, Sister Pat Sullivan, Sister
Sandra Coats, Sister Linda Tallon, Sister
Marion Gillen, Midwife Gail Halleron, and Pe-
ter Clinton. Glasgow Royal Maternity Hospi-
tal, Glasgow: Dr. Angus MacCuish, Dr. C.
Burnett Lunan, Dr. Kenneth Paterson, Dr.
Layla Alroomi, Sister Tricia Kelly, Sister Liz
Winn, Staff Anne Harris, and Ian Thomas.
Ninewells Hospital, Dundee: Dr. Graham P.
Leese, Dr. Gary J. Mires, Dr. Peter W. Fowlie,
Sister Mary Robertson, Midwife Anne E. Stur-
rock, Midwife Paula Thomson, and Dr. Jimmy
Burns. The Queen Mother’s Maternity Hospi-
tal, Glasgow: Dr. Michael Small, Dr. Alan D.
Cameron, Dr. Thomas L. Turner, Sister
Brenda Capaldi, Sister Anne Byrne, MBE, Mid-
wife Cindy Horan, Midwife Sheila Lee, Dr.
Chris Hillier, and Richard Webber. Raigmore
Hospital Inverness: Dr. Sandra M. MacRury,
Dr. D.A. Russell Lees, Paed., Dr. Ian Mac-
Donald, Dr. Liz McFarlane, Midwife Marie
McDonald, Sister Jenny Lobban, Midwife
Karen Marnoch, and Angela Veitch. Simpson
Memorial Maternity Pavilion, Edinburgh: Dr.
James D. Walker, Dr. Hilary D. MacPherson,
Dr. Alan Patrick, Dr. John A. McKnight, Dr.
Ian A. Laing, Sister Shonagh Battison, Staff
Joan Grant, Staff Liz McKay, Midwife Jackie
Rankine, Midwife Jacqui Ravie, Midwife Tricia
Taylor, Midwife Fiona McNeilage, Midwife
Marie MacAulay, Midwife Mhairi Allen, John
Scott, and David Hargreaves.
Additional help and advice was obtained
from Dr. Gillian Penney (Scottish Program for
Clinical Effectiveness in Reproductive Health),
Professor Gillian Raab (Napier University, Ed-
inburgh, U.K.), and Fiona Tulloch and Brian
Misson (Cambridge).
References
1. Scherer PE, Williams S, Fogliano M, Bal-
dini G, Lodish HF: A novel serum protein
similar to C1q produced exclusively in
adipocytes. J Biol Chem 270:26746–
26749, 1995
2. Hu E, Liang P, Spiegelman BM: AdipoQ is
a novel adipose-specific gene dysregu-
lated in obesity. J Biol Chem 271:10697–
10703, 1996
3. Matsubara M, Maruoka S, Katayose S: In-
verse relationship between plasma adi-
ponectin and leptin concentrations in
normal-weight and obese women. Eur J
Endocrinol 147:173–180, 2002
4. Hotta K, Funahashi T, Arita Y, Takahashi
M, Matsuda M, Okamoto Y, Iwahashi H,
Kuriyama H, Ouchi N, Maeda K, Nishida
M, Kihara S, Sakai N, Nakajima T, Ha-
segawa K, Muraguchi M, Ohmoto Y,
Nakamura T, Yamashita S, Hanafusa T,
Matsuzawa Y: Plasma concentrations of a
novel, adipose-specific protein, adiponec-
tin, in type 2 diabetic patients. Arterioscler
Thromb Vasc Biol 20:1595–1599, 2000
5. Weyer C, Funahashi T, Tanaka S, Hotta K,
Matsuzawa Y, Pratley RE, Tataranni PA:
Hypoadiponectinemia in obesity and type
2 diabetes: close association with insulin
resistance and hyperinsulinemia. J Clin
Endocrinol Metab 86:1930–1935, 2001
6. Yang WS, Lee WJ, Funahashi T, Tanaka S,
Matsuzawa Y, Chao CL, Chen CL, Tai TY,
Chuang LM: Weight reduction increases
plasma levels of an adipose-derived anti-
inflammatory protein, adiponectin. J Clin
Endocrinol Metab 86:3815–3819, 2001
7. Maeda N, Takahashi M, Funahashi T,
Kihara S, Nishizawa H, Kishida K, Naga-
retani H, Matsuda M, Komuro R, Ouchi
N, Kuriyama H, Hotta K, Nakamura T,
Shimomura I, Matsuzawa Y: PPAR	 li-
gands increase expression and plasma
concentrations of adiponectin, an adi-
pose-derived protein. Diabetes 50:2094–
2099, 2001
8. Lindsay RS, Funahashi T, Hanson RL,
Matsuzawa Y, Tanaka S, Tataranni PA,
Knowler WC, Krakoff J: Adiponectin and
development of type 2 diabetes in the
Pima Indian population. Lancet 360:57–
58, 2002
9. Pedersen J: Weight and length at birth in
infants of diabetic mothers. Acta Endocri-
nologica 16:330–342, 1954
10. Tapanainen P, Leinonen E, Ruokonen A,
Knip M: Leptin concentrations are ele-
vated in newborn infants of diabetic
mothers. Horm Res 55:185–190, 2001
11. Freinkel N: Banting Lecture 1980: of
pregnancy and progeny. Diabetes 29:
1023–1035, 1980
12. Pettitt DJ, Baird HR, Aleck KA, Bennett
PH, Knowler WC: Excessive obesity in
offspring of Pima Indian women with di-
abetes during pregnancy. N Engl J Med
308:242–245, 1983
13. Silverman BL, Landsberg L, Metzger BE:
Fetal hyperinsulinism in offspring of dia-
betic mothers: association with the subse-
quent development of childhood obesity.
Ann N Y Acad Sci 699:36–45, 1993
14. Pettitt DJ, Nelson RG, Saad MF, Bennett
PH, Knowler WC: Diabetes and obesity in
the offspring of Pima Indian women with
diabetes during pregnancy. Diabetes Care
16 (Suppl. 1):310–314, 1993
15. Weiss PAM, Scholz HS, Haas J, Ta-
mussino KF, Seissler J, Borkenstein MH:
Long-term follow-up of infants of moth-
ers with type 1 diabetes: evidence for he-
reditary and nonhereditary transmission
of diabetes and precursors. Diabetes Care
23:905–911, 2000
16. Plagemann A, Harder T, Kohlhoff R, Ro-
hde W, Dorner G: Glucose tolerance and
insulin secretion in children of mothers
with pregestational IDDM or gestational
diabetes.Diabetologia 40:1094–1100, 1997
17. Silverman BL, Metzger BE, Cho NH, Loeb
CA: Impaired glucose tolerance in adoles-
cent offspring of diabetic mothers: rela-
tionship to fetal hyperinsulinism.Diabetes
Care 18:611–617, 1995
18. Lindsay RS, Walker JD, Halsall I, Hales
CN, Calder AA, Hamilton BA, Johnstone
FD, the Scottish Multicentre Study of Di-
abetes in Pregnancy: Insulin and insulin
propeptides at birth in offspring of dia-
betic mothers. J Clin Endocrinol Metab 88:
1664–1671, 2003
19. Johnstone FD, Mao JH, Steel JM, Prescott
RJ, Hume R: Factors affecting fetal weight
distribution in women with type I diabe-
tes. BJOG 107:1001–1006, 2000
20. Cnop M, Havel PJ, Utzschneider KM, Carr
DB, Retzlaff BJ, Knopp RH, Kahn SE: Gen-
der-based differences in adiponectin and
leptin levels are related to differences in
body fat distribution (Abstract). Diabetes
51 (Suppl. 2):A404, 2002
21. Havel PJ, Stanhope KJ, Sinha M, Dubuc
GR, Phinney SD: Gender differences in
circulating adiponectin concentrations
and in adiponectin responses to 7 days
of energy restriction in normal weight
men and women (Abstract). Diabetes 51
(Suppl. 2):A454, 2002
22. Berg AH, Combs TP, Du X, Brownlee M,
Scherer PE: The adipocyte-secreted pro-
tein Acrp30 enhances hepatic insulin ac-
tion. Nat Med 7:947–953, 2001
23. Combs TP, Berg AH, Obici S, Scherer PE,
Rossetti L: Endogenous glucose produc-
tion is inhibited by the adipose-derived
protein Acrp30. J Clin Invest 108:1875–
1881, 2001
24. Yamauchi T, Kamon J, Waki H, Terauchi
Y, Kubota N, Hara K, Mori Y, Ide T, Mu-
rakami K, Tsuboyama-Kasaoka N, Ezaki
O, Akanuma Y, Gavrilova O, Vinson C,
Adiponectin in cord blood
2248 DIABETES CARE, VOLUME 26, NUMBER 8, AUGUST 2003
Reitman ML, Kagechika H, Shudo K,
Yoda M, Nakano Y, Tobe K, Nagai R,
Kimura S, Tomita M, Froguel P, Kad-
owaki T: The fat-derived hormone adi-
ponectin reverses insulin resistance
associated with both lipoatrophy and
obesity. Nat Med 7:941–946, 2001
25. Fruebis J, Tsao TS, Javorschi S, Ebbets-
Reed D, Erickson MR, Yen FT, Bihain BE,
Lodish HF: Proteolytic cleavage product
of 30-kDa adipocyte complement-related
protein increases fatty acid oxidation in
muscle and causes weight loss in mice.
Proc Natl Acad Sci U S A 98:2005–2010,
2001
26. Ouchi N, Kihara S, Arita Y, Okamoto Y,
Maeda K, Kuriyama H, Hotta K, Nishida
M, Takahashi M, Muraguchi M, Ohmoto
Y, Nakamura T, Yamashita S, Funahashi
T, Matsuzawa Y: Adiponectin, an adipo-
cyte-derived plasma protein, inhibits en-
dothelial NF-kappaB signaling through a
cAMP-dependent pathway. Circulation
102:1296–1301, 2000
27. Masuzaki H, Ogawa Y, Sagawa N, Hosoda
K, Matsumoto T, Mise H, Nishimura H,
Yoshimasa Y, Tanaka I, Mori T, Nakao K:
Nonadipose tissue production of leptin:
leptin as a novel placenta-derived hor-
mone in humans. Nat Med 3:1029–1033,
1997
28. Arita Y, Kihara S, Ouchi N, Takahashi M,
Maeda K, Miyagawa J, Hotta K, Shimo-
mura I, Nakamura T, Miyaoka K, Kuri-
yama H, Nishida M, Yamashita S, Okubo
K, Matsubara K, Muraguchi M, Ohmoto
Y, Funahashi T, Matsuzawa Y: Paradoxi-
cal decrease of an adipose-specific pro-
tein, adiponectin, in obesity. Biochem
Biophys Res Commun 257:79–83, 1999
29. Comuzzie AG, Funahashi T, Sonnenberg
G, Martin LJ, Jacob HJ, Black AE, Maas D,
Takahashi M, Kihara S, Tanaka S, Matsu-
zawa Y, Blangero J, Cohen D, Kissebah A:
The genetic basis of plasma variation in
adiponectin, a global endophenotype for
obesity and the metabolic syndrome.
J Clin Endocrinol Metab 86:4321–4325,
2001
30. Zoccali C, Mallamaci F, Tripepi G, Bene-
detto FA, Cutrupi S, Parlongo S, Malatino
LS, Bonanno G, Seminara G, Rapisarda F,
Fatuzzo P, Buemi M, Nicocia G, Tanaka S,
Ouchi N, Kihara S, Funahashi T, Matsu-
zawa Y: Adiponectin, metabolic risk fac-
tors, and cardiovascular events among
patients with end-stage renal disease. J Am
Soc Nephrol 13:134–141, 2002
31. Fasshauer M, Klein J, Neumann S, Es-
zlinger M, Paschke R: Hormonal regula-
tion of adiponectin gene expression in
3T3–L1 adipocytes. Biochem Biophys Res
Commun 290:1084–1089, 2002
32. Halleux CM, Takahashi M, Delporte ML,
Detry R, Funahashi T, Matsuzawa Y, Bri-
chard SM: Secretion of adiponectin and
regulation of apM1 gene expression in hu-
man visceral adipose tissue. Biochem Bio-
phys Res Commun 288:1102–1107, 2001
33. Imagawa A, Funahashi T, Nakamura T,
Moriwaki M, Tanaka S, Nishizawa H,
Sayama K, Uno S, Iwahashi H, Yamagata
K, Miyagawa JI, Matsuzawa Y: Elevated
serum concentration of adipose-derived
factor, adiponectin, in patients with type
1 diabetes (Letter). Diabetes Care 25:
1665–1666, 2002
34. Hamalainen AM, Ronkainen MS, Aker-
blom HK, Knip M: Postnatal elimination
of transplacentally acquired disease-asso-
ciated antibodies in infants born to fami-
lies with type 1 diabetes: the Finnish
TRIGR (Trial to Reduce IDDM in the Ge-
netically at Risk) Study Group. J Clin En-
docrinol Metab 85:4249–4253, 2000
35. Menon RK, Cohen RM, Sperling MA, Cut-
field WS, Mimouni F, Khoury JC: Trans-
placental passage of insulin in pregnant
women with insulin-dependent diabetes
mellitus: its role in fetal macrosomia.
N Engl J Med 323:309–315, 1990
36. Nishizawa H, Shimomura I, Kishida K,
Maeda N, Kuriyama H, Nagaretani H,
Matsuda M, Kondo H, Furuyama N,
Kihara S, Nakamura T, Tochino Y, Fu-
nahashi T, Matsuzawa Y: Androgens de-
crease plasma adiponectin, an insulin-
sensitizing adipocyte-derived protein.
Diabetes 51:2734–2741, 2002
37. Catalano PM, Thomas AJ, Huston LP,
Fung CM: Effect of maternal metabolism
on fetal growth and body composition.
Diabetes Care 21 (Suppl. 2):B85–B90,
1998
38. Simmons D, France JT, Keelan JA, Song
L, Knox BS: Sex differences in umbilical
cord serum levels of inhibin, testosterone,
oestradiol, dehydroepiandrosterone sul-
phate, and sex hormone-binding globulin
in human term neonates. Biol Neonate 65:
287–294, 1994
39. Simmons D: Interrelation between um-
bilical cord serum sex hormones, sex
hormone-binding globulin, insulin-like
growth factor I, and insulin in neonates
from normal pregnancies and pregnan-
cies complicated by diabetes. J Clin Endo-
crinol Metab 80:2217–2221, 1995
40. Tsao TS, Murrey HE, Hug C, Lee DH,
Lodish HF: Oligomerization state-depen-
dent activation of NF-kB signaling path-
way by Acrp30. J Biol Chem 277:29359–
29362, 2002
41. Wang Y, Xu A, Knight C, Xu LY, Cooper
GJ: Hydroxylation and glycosylation of
the four conserved lysine residues in the
collagenous domain of adiponectin: po-
tential role in the modulation of its insu-
lin-sensitizing activity. J Biol Chem 277:
19521–19529, 2002
Lindsay and Associates
DIABETES CARE, VOLUME 26, NUMBER 8, AUGUST 2003 2249
